Skip to main content
Top
Published in: Rheumatology International 5/2010

01-03-2010 | Original Article

Annual costs of rheumatoid arthritis in Turkey

Authors: Simten Malhan, Lale Aktekın Akbulut, Hatice Bodur, Cankat F. Tulunay

Published in: Rheumatology International | Issue 5/2010

Login to get access

Abstract

Objective of the present study is aimed to determine costs of rheumatoid arthritis (RA) based on reimbursement agencies perspective [Social Security Institution(SSI)] in Turkey. The international clinical guidelines for RA are followed for analysing the direct costs. Data were collected from hospital bills, social security institution price lists, and Ministry of Health drug price list. Direct costs of RA patients were estimated as €2,669.14 patient/year. Outpatient costs were found to be €240.40. Routine tests during the year were calculated as €98.85. Ten percent of patients are hospitalized per year, and 0.62% of these patients received arthroplasty and/or other interventions. The cost during hospital stay was €87.76. €2,238 was determined as being paid per year for medication alone (including anti-TNF) and €4 is spent on auxiliary materials annually. Our data show a remarkable economic impact of RA over society. We hope that the cost of RA studies will help package price practices for reimbursement agencies.
Literature
3.
go back to reference Turkish Republic Ministry of Health Refik Saydam Hygiene Center Presidency School of Public Health, “National Burden of Disease and Cost Effectiveness Study” 2005 Turkish Republic Ministry of Health Refik Saydam Hygiene Center Presidency School of Public Health, “National Burden of Disease and Cost Effectiveness Study” 2005
5.
go back to reference Kobelt G, Eberhardt K, Geborek P (2004) TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden. Ann Rheum Dis 63:4–10. doi:10.1136/ard.2003.010629 CrossRefPubMed Kobelt G, Eberhardt K, Geborek P (2004) TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden. Ann Rheum Dis 63:4–10. doi:10.​1136/​ard.​2003.​010629 CrossRefPubMed
9.
go back to reference Péntek M, Kobelt G, Czirják L, Szekanecz Z, Poor G, Rojkovich B et al (2007) Costs of rheumatoid arthritis in Hungary. J Rheumatol 34:1437PubMed Péntek M, Kobelt G, Czirják L, Szekanecz Z, Poor G, Rojkovich B et al (2007) Costs of rheumatoid arthritis in Hungary. J Rheumatol 34:1437PubMed
12.
go back to reference Combe B, Landewe R, Lukas C, Bolosiu HD, Breedveld F, Dougados M (2007) EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 66(1):34–45. doi:10.1136/ard.2005.044354 CrossRefPubMed Combe B, Landewe R, Lukas C, Bolosiu HD, Breedveld F, Dougados M (2007) EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 66(1):34–45. doi:10.​1136/​ard.​2005.​044354 CrossRefPubMed
13.
go back to reference Maetzel A, Tugwell P, Boers M, Guillemin F, Coyle D, Drummond M et al (2003) Economic evaluation of programs or interventions in the management of rheumatoid arthritis: defining a consensus-based reference case. J Rheumatol 30:891–896PubMed Maetzel A, Tugwell P, Boers M, Guillemin F, Coyle D, Drummond M et al (2003) Economic evaluation of programs or interventions in the management of rheumatoid arthritis: defining a consensus-based reference case. J Rheumatol 30:891–896PubMed
14.
go back to reference Gabriel S, Drummond M, Maetzel A, Boers M, Coyle D, Welch V et al (2003) OMERACT 6 Economics Working Group report: a proposal for a reference case for economic evaluation in rheumatoid arthritis. J Rheumatol 30:886–890PubMed Gabriel S, Drummond M, Maetzel A, Boers M, Coyle D, Welch V et al (2003) OMERACT 6 Economics Working Group report: a proposal for a reference case for economic evaluation in rheumatoid arthritis. J Rheumatol 30:886–890PubMed
15.
go back to reference Bodur H, Ataman S, Akbulut L, Evcik D, Kavuncu V, Kaya T et al (2008) Characteristics and medical management of patients with rheumatoid arthritis and ankylosing spondylitis. Clin Rheumatol 27:1119–1125. doi:10.1007/s10067-008-0877-1 CrossRefPubMed Bodur H, Ataman S, Akbulut L, Evcik D, Kavuncu V, Kaya T et al (2008) Characteristics and medical management of patients with rheumatoid arthritis and ankylosing spondylitis. Clin Rheumatol 27:1119–1125. doi:10.​1007/​s10067-008-0877-1 CrossRefPubMed
16.
go back to reference T.C. Sağlık Bakanlığı İlaç Eczacılık Genel Müdürlüğü Temel İlaç Fiyat listesi T.C. Sağlık Bakanlığı İlaç Eczacılık Genel Müdürlüğü Temel İlaç Fiyat listesi
17.
go back to reference T.C. Sosyal Güvenlik Kurumu Sağlık Uygulama Tebliği T.C. Sosyal Güvenlik Kurumu Sağlık Uygulama Tebliği
18.
go back to reference Cowley P, Bodabilla L, Musgrove P, Saxenian H (1994) Content and Financing of an essential national package of health services, global assessments in the health sector, World Health Organization, pp 171–181 Cowley P, Bodabilla L, Musgrove P, Saxenian H (1994) Content and Financing of an essential national package of health services, global assessments in the health sector, World Health Organization, pp 171–181
20.
go back to reference Clarke AE, Zowall H, Levinton C, Assimakopoulos H, Sibley JT, Haga M et al (1997) Direct and indirect medical costs incurred by Canadian patients with rheumatoid arthritis: a 12 year study. J Rheumatol 24:1051–1060PubMed Clarke AE, Zowall H, Levinton C, Assimakopoulos H, Sibley JT, Haga M et al (1997) Direct and indirect medical costs incurred by Canadian patients with rheumatoid arthritis: a 12 year study. J Rheumatol 24:1051–1060PubMed
Metadata
Title
Annual costs of rheumatoid arthritis in Turkey
Authors
Simten Malhan
Lale Aktekın Akbulut
Hatice Bodur
Cankat F. Tulunay
Publication date
01-03-2010
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 5/2010
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-009-1040-2

Other articles of this Issue 5/2010

Rheumatology International 5/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine